Advances in DNA Sequence-specific Agents ( Volume 3 )

Publication series :Volume 3

Author: Palumbo   M.  

Publisher: Elsevier Science‎

Publication year: 1997

E-ISBN: 9780080544557

P-ISBN(Paperback): 9780762302031

P-ISBN(Hardback):  9780762302031

Subject: Q523 deoxyribonucleic acid (DNA)

Language: ENG

Access to resources Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Description

In this volume the entire focus is devoted to the macromolecule target specificity of DNA interactive developmental therapeutic agents of current interest.
A brief introduction to DNA interactive anticancer agents is included for readers who may benefit from an overview surrounding the developments that have contributed to our general understanding of this field. The following nine chapters have been carefully chosen so that they describe topics which are at the forefront of development in DNA-targeted cancer chemotherapy. Issues that have been addressed include the mechanisms of selective DNA topoisomerase I and II poisoning by antitumor agents (Chapters 1 and 2), sequence-specific recognition of DNA by groove-binding drugs and drug-conjugates (Chapters 3 and 4), recent developments in nitrogen mustard alkylating agents and their potential use for antibody-directed enzyme-prodrug therapy (Chapter 5), nonclassical platinum anticancer complexes, including dinuclear and trans-platinum derivatives (Chapter 6), DNA cleaving antitumor chromoproteins containing reactive enediyne moieties, which exhibit interesting free-radical chemistry along with selective targeting (Chapter 7), the potential of new sequence-specific antisense and antigene therapy in oncology (Chapter 8), and finally the conceivable chemotherapeutic use of mimetics of the DNA structure, obtained by substitution of the sugar-phosphate natural chain with a peptide backbone, the so-called peptide nucleic acids (C

Chapter

Cover

pp.:  1 – 4

Copyright Page

pp.:  5 – 6

CONTENTS

pp.:  6 – 8

LIST OF CONTRIBUTORS

pp.:  8 – 10

PREFACE

pp.:  10 – 12

CHAPTER 2. SEQUENCE-SPECIFIC POISONS OF TYPE II DNA TOPOISOMERASES

pp.:  18 – 50

CHAPTER 3. TOPOISOMERASE I-TARGETING DRUGS: NEW DEVELOPMENTS IN CANCER PHARMACOLOGY

pp.:  50 – 78

CHAPTER 4. DNA SEQUENCE RECOGNITION ALTERED BIS-BENZIMIDAZOLE MINOR-GROOVE BINDERS

pp.:  78 – 108

CHAPTER 5. SEQUENCE-SPECIFIC RECOGNITION AND MODIFICATION OF DOUBLE-HELICAL DNA BY MINOR-GROOVE BINDING CONJUGATES STRUCTURALLY RELATED TO NETROPSIN AND DISTAMYCIN

pp.:  108 – 168

CHAPTER 6. NEW DEVELOPMENTS IN THE USE OF NITROGEN MUSTARD ALKYLATING AGENTS AS ANTICANCER DRUGS

pp.:  168 – 190

CHAPTER 7. DNA BINDING OF NONCLASSICAL PLATINUM ANTITUMOR COMPLEXES

pp.:  190 – 212

CHAPTER 8. KEDARCIDIN AND MADUROPEPTIN: TWO NOVEL ANTITUMOR CHROMOPROTEINS WITH SELECTIVE PROTEASE ACTIVITY AND DNA CLEAVING PROPERTIES

pp.:  212 – 238

CHAPTER 9. ANTISENSE- AND ANTIGENE-BASED DRUG DESIGN STRATEGIES IN ONCOLOGY

pp.:  238 – 278

CHAPTER 10. SEQUENCE-SPECIFIC RECOGNITION OF DOUBLE-STRANDED DNA BY PEPTIDE NUCLEIC ACIDS

pp.:  278 – 290

INDEX

pp.:  290 – 298

The users who browse this book also browse